Sagimet BiosciencesSTU:0O2 +1.66%10 3-Year Share Buyback Ratio is -13.60 as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,200 Biotechnology companies, Sagimet Biosciences ranks worse than 53.67% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Sagimet Biosciences's current 3-Year Share Buyback Ratio was -13.60%.
The historical rank and industry rank for Sagimet Biosciences's 3-Year Share Buyback Ratio or its related term are showing as below:
STU:0O2'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6 Med: -7.15 Max: 0
Current: -13.6
During the past 7 years, Sagimet Biosciences's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -13.60%. And the median was -7.15%.
STU:0O2's 3-Year Share Buyback Ratio is ranked worse than 53.67% of 1200
companies
in the Biotechnology industry
Industry Median: -11.95
vs STU:0O2: -13.60
Sagimet Biosciences (STU:0O2) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Sagimet Biosciences 3-Year Share Buyback Ratio Related Terms
STU:0O2 vs EDIT, AUTL, FBRX: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Sagimet Biosciences's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's 3-Year Share Buyback Ratio falls into.
Sagimet Biosciences 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -13.60 mean?
Sagimet Biosciences (STU:0O2) has a 3-Year Share Buyback Ratio of -13.60 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Sagimet Biosciences and its competitors. According to the industry distribution chart, Sagimet Biosciences ranks #644 out of 1200 companies in the Biotechnology industry, placing it in the top 53.7%.
Is Sagimet Biosciences' 3-Year Share Buyback Ratio too high?
Sagimet Biosciences' current 3-Year Share Buyback Ratio is -13.60. Based on the distribution chart, Sagimet Biosciences ranks #644 out of 1200 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' 3-Year Share Buyback Ratio compare to EDIT and AUTL?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #644 out of 1200 companies for 3-Year Share Buyback Ratio. This places Sagimet Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Sagimet Biosciences and its competitors. Sagimet Biosciences's current 3-Year Share Buyback Ratio is -13.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current 3-Year Share Buyback Ratio of -13.60. The current 3-Year Share Buyback Ratio is -13.60. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current 3-Year Share Buyback Ratio is -13.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 